Nb62-r-mAb

Nb62-r-mAb is a brain-penetrant recombinant monoclonal antibody fusion protein designed to inhibit the complement system in the central nervous system. It consists of the complement C7-blocking monoclonal antibody clone 73D1 (grafted onto a modified mouse IgG2a framework with a D265A mutation to ablate Fc receptor binding) fused at the carboxy terminus of one heavy chain to a nanobody, Nb62, which targets the transferrin receptor (TfR). The Nb62 nanobody acts as a molecular shuttle, facilitating receptor-mediated transcytosis across the blood-brain barrier (BBB). By binding to C7, Nb62-r-mAb prevents the assembly of the membrane attack complex (MAC), thereby reducing neuroinflammation, microgliosis, and synaptic loss. It is being investigated for the treatment of neurodegenerative disorders, specifically Alzheimer's disease.

Other names

73D1-Nb62anti-C7 mAb 73D1 fused with nanobody Nb62anti-C-7 mAb 73D1 fused with nanobody Nb62anti-C 7 mAb 73D1 fused with nanobody Nb62Nb62-linked 73D1Nb-62-linked 73D1Nb 62-linked 73D1Nb62-linked recombinant mAbNb-62-linked recombinant mAbNb 62-linked recombinant mAb